N

Nasus Pharma Ltd. (NSRX)

ASE – Real vaqt narxi. Valyuta: USD

2.49

-0.01 (-0.40%)

Yopilishda: Mar 24, 2026, 4:00 PM EDT

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Barcha huquqlar himoyalangan.

Foydalanish shartlari

N

Nasus Pharma Ltd. (NSRX)

ASE – Real vaqt narxi. Valyuta: USD

2.49

-0.01 (-0.40%)

Yopilishda: Mar 24, 2026, 4:00 PM EDT

19.08.2026

Nasus Pharma Announces Transition of Chief Financial Officer

TEL AVIV, Israel, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE American: NSRX) ("Nasus", “Nasus Pharma” or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that Chief Financial Officer, Eyal Rubin, will be leaving the Company to pursue a new opportunity outside of the life science industry.

17.08.2026

Nasus Pharma Reports First Half 2026 Financial Results and Provides Business Update

Appointed Pharma Industry Veteran Brendan O'Grady as Chief Executive Officer Company on Track to Advance Clinical Programs to Key Second Half 2026 Milestones TEL AVIV, Israel, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus", “Nasus Pharma” or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced its financial results for the six months ending June 30, 2026 and provided a corporate update.

Videolar

No Data

There is no data to display

Press-relizlar

19.08.2026

Nasus Pharma Announces Transition of Chief Financial Officer

TEL AVIV, Israel, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE American: NSRX) ("Nasus", “Nasus Pharma” or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that Chief Financial Officer, Eyal Rubin, will be leaving the Company to pursue a new opportunity outside of the life science industry.

17.08.2026

Nasus Pharma Reports First Half 2026 Financial Results and Provides Business Update

Appointed Pharma Industry Veteran Brendan O'Grady as Chief Executive Officer Company on Track to Advance Clinical Programs to Key Second Half 2026 Milestones TEL AVIV, Israel, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus", “Nasus Pharma” or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced its financial results for the six months ending June 30, 2026 and provided a corporate update.

Search stocks

Nasus Pharma Ltd. (NSRX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Nasus Pharma Ltd. (NSRX)

Nasus Pharma Announces Transition of Chief Financial Officer

Nasus Pharma Reports First Half 2026 Financial Results and Provides Business Update

Videolar

No Data

Press-relizlar

Nasus Pharma Announces Transition of Chief Financial Officer

Nasus Pharma Reports First Half 2026 Financial Results and Provides Business Update